Compare RCMT & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | SGMO |
|---|---|---|
| Founded | 1971 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 141.2M |
| IPO Year | 1997 | 2000 |
| Metric | RCMT | SGMO |
|---|---|---|
| Price | $27.50 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 60.1K | ★ 6.8M |
| Earning Date | 04-03-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | 10.20 |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $186,737,000.00 | $36,567,000.00 |
| Revenue This Year | $16.29 | $24.46 |
| Revenue Next Year | $6.92 | $193.67 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | 5.83 | ★ 88.60 |
| 52 Week Low | $15.29 | $0.21 |
| 52 Week High | $28.19 | $0.84 |
| Indicator | RCMT | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 82.25 | 33.87 |
| Support Level | $26.23 | $0.21 |
| Resistance Level | N/A | $0.55 |
| Average True Range (ATR) | 1.34 | 0.04 |
| MACD | 0.98 | -0.01 |
| Stochastic Oscillator | 96.68 | 24.14 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.